Fluidx Medical Begins Multinational Trial of GPX Embolic Device

December 5, 2024

November 27, 2024—Fluidx Medical Technology, Inc. announced that the first patient has been treated in the prospective, multinational, clinical trial of the company’s GPX embolic device. The device was successfully used in a portal vein embolization procedure in preparation for hepatic resection.

According to the company, the safety and effectiveness trial includes leading medical centers and investigators from the United States, Canada, and New Zealand. In May 2024, the company announced FDA approval of the investigational device exception for the GPX trial.

The initial procedure was discussed in the Fluidx press release by Stephen Chen, MD, who is the principal investigator at MD Anderson Cancer Center in Houston, Texas.

“We are pleased with the complete vessel filling we observed,” commented Dr. Chen. “GPX was easy to prepare, deliver, and use. We could see the material flow distally into the vessel segment, completely blocking blood flow to the target area. This was exactly what we were aiming for.”